Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT

Mahboob Rahman, Charles Baimbridge, Barry R. Davis, Joshua I. Barzilay, Jan N. Basile, Mario A. Henriquez, Anne Huml, Nelson Kopyt, Gail T. Louis, Sara L. Pressel, Clive Rosendorff, Sithiporn Sastrasinh, Carol Stanford

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background/Aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by baseline estimated glomerular filtration rate (eGFR). Methods: Post-hoc analyses of a prospective randomized open-label clinical trial; 10,151 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) were randomized to pravastatin 40 mg/day or usual care. Mean follow-up was 4.8 years. Results: Through Year 6, total cholesterol declined in pravastatin (-20.7%) and usualcare groups (-11.2%). Use of statin therapy in the pravastatin group was 89.8% (Year 2) and 87.0% (Year 6). Usual-care group statin use increased from 8.2% (Year 2) to 23.5% (Year 6). By primary intention-to-treat analyses, no significant differences were seen between groups for coronary heart disease (CHD), total mortality or combined cardiovascular disease; findings were consistent across eGFR strata. In exploratory "as-treated" analyses (patients actually using pravastatin vs. not using), pravastatin therapy was associated with lower mortality (HR = 0.76 (0.68 - 0.85), p < 0.001) and lower CHD (HR = 0.84 (0.73 - 0.97), p = 0.01), but not combined cardiovascular disease (HR = 0.95 (0.88 - 1.04), p = 0.30). Total cholesterol reduction of 10 mg/dl from baseline to Year 2 was associated with 5% lower CHD risk. Conclusions: In hypertensive patients with moderate dyslipidemia, pravastatin was not superior to usual care in preventing total mortality or CHD independent of baseline eGFR level. However, exploratory "as-treated" analyses suggest improved mortality and CHD risk in participants using pravastatin, and decreased CHD events associated with achieved reduction in total cholesterol. Potential benefit from statin therapy may depend on degree of reduction achieved in total and LDL-cholesterol and adherence to therapy.

Original languageEnglish
Pages (from-to)235-248
Number of pages14
JournalClinical Nephrology
Issue number4
StatePublished - 2013


  • Disease-cardiovascular
  • Hyperlipidemia-kidney
  • Outcomes-chronic
  • Renal failure


Dive into the research topics of 'Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT'. Together they form a unique fingerprint.

Cite this